Antimicrobial Agents — MCQs

Antimicrobial Agents Indian Medical PG Practice Questions and MCQs

Question 1531: Which antitubercular drug makes the patient non-infective the earliest?

A. Ethambutol
B. Pyrazinamide
C. Isoniazid (INH) (Correct Answer)
D. Rifampin

Explanation: ***Isoniazid (INH)*** - **Isoniazid** renders TB patients **non-infectious the fastest**, typically within **2-3 days** of starting treatment - It has the most **rapid bactericidal effect** against actively multiplying extracellular **Mycobacterium tuberculosis**, which are the primary organisms responsible for transmission - INH works by inhibiting **mycolic acid synthesis**, disrupting the bacterial cell wall of rapidly dividing bacilli - This makes it the most critical drug for **early infection control** and reducing community transmission *Rifampin* - While **rifampin** is highly bactericidal and has excellent sterilizing activity, it takes **slightly longer** than INH to render patients non-infectious - Rifampin is particularly effective against **semi-dormant organisms** and intracellular bacilli - It is the most important drug for **preventing relapse** and shortening treatment duration, but INH acts faster in reducing infectivity *Ethambutol* - **Ethambutol** is primarily **bacteriostatic**, inhibiting arabinosyl transferase and interfering with cell wall synthesis - Its main role is to **prevent emergence of drug resistance** rather than rapidly reducing bacterial load - Has minimal impact on early infectivity reduction *Pyrazinamide* - **Pyrazinamide** is most effective against **semi-dormant bacilli** within macrophages and in acidic environments - Its **sterilizing activity** helps shorten overall treatment duration but does not contribute significantly to rapid reduction in infectivity - Works slowly and is not bactericidal against actively multiplying extracellular organisms

Question 1532: Idoxuridine is used for treatment of?

A. Influenza
B. RSV
C. HSV (Correct Answer)
D. HIV

Explanation: ***HSV*** - **Idoxuridine** is a **pyrimidine analog** that inhibits viral DNA synthesis, making it effective against **herpes simplex virus (HSV)** infections, particularly **herpes keratitis** (ophthalmic use). - Its mechanism involves being incorporated into viral DNA, leading to errors in replication and transcription. - It is applied **topically** for ocular HSV infections due to systemic toxicity concerns. *Influenza* - **Idoxuridine** is not active against **influenza viruses**. - **Antiviral drugs** like **oseltamivir** or **zanamivir** are typically used for influenza treatment. *RSV* - **Idoxuridine** is not indicated for the treatment of **respiratory syncytial virus (RSV)**. - **Ribavirin** is the primary antiviral agent used for severe RSV infections, especially in immunocompromised patients. *HIV* - **Idoxuridine** has no significant activity against **human immunodeficiency virus (HIV)**. - **Antiretroviral therapy (ART)**, a combination of drugs targeting various stages of the HIV life cycle, is used for HIV treatment.

Question 1533: Thymidine is responsible for resistance to which antibiotic ?

A. Erythromycin
B. Sulfonamide (Correct Answer)
C. Tetracycline
D. Nitrofurantoin

Explanation: ***Sulfonamide*** - **Thymidine** can contribute to **sulfonamide resistance** because sulfonamides interfere with **folate metabolism** and the subsequent synthesis of purines and pyrimidines, including thymidine. - An excess of thymidine can bypass the metabolic block caused by sulfonamides, allowing bacteria to continue DNA synthesis and grow. *Erythromycin* - **Erythromycin** resistance is primarily mediated by **methylation of ribosomal RNA**, which prevents the antibiotic from binding to the 50S ribosomal subunit. - It does not directly involve thymidine or the folate synthesis pathway. *Tetracycline* - Resistance to **tetracyclines** is commonly due to **efflux pumps** that actively pump the drug out of the bacterial cell or **ribosomal protection proteins** that prevent tetracycline binding. - Thymidine production or metabolism is not a mechanism of tetracycline resistance. *Nitrofurantoin* - **Nitrofurantoin** resistance typically involves **mutations** in bacterial enzymes (like **nitrofuran reductase**) that are responsible for activating the drug into its active form. - These mutations prevent the drug from becoming bactericidal, and thymidine does not play a role in this mechanism.

Question 1534: Emtricitabine is classified as which of the following?

A. Alkylating agent
B. Antimetabolite
C. NRTI (Correct Answer)
D. Integrase Inhibitor

Explanation: ***NRTI*** - Emtricitabine is a **nucleoside reverse transcriptase inhibitor (NRTI)**, a class of antiretroviral drugs used in the treatment of **HIV infection**. - As an NRTI, it works by inhibiting the enzyme **reverse transcriptase**, which is crucial for the HIV virus to replicate its RNA into DNA. *Alkylating agent* - Alkylating agents are a type of **chemotherapy drug** that kill cancer cells by damaging their DNA. - They are primarily used in **cancer treatment**, not for viral infections like HIV. *Antimetabolite* - Antimetabolites are drugs that interfere with DNA and RNA synthesis, often used in **chemotherapy** to treat cancer or in immunosuppression. - While they can inhibit nucleic acid synthesis, this is a broad category, and emtricitabine's specific mechanism and classification are as an NRTI. *Integrase Inhibitor* - Integrase inhibitors are another class of **antiretroviral drugs** that block the HIV enzyme integrase, preventing the viral DNA from integrating into the host cell's DNA. - While an antiretroviral, emtricitabine has a different mechanism of action and belongs to the NRTI class.

Question 1535: Emtricitabine is a/an:

A. Alkylating agent
B. Mitotic inhibitor
C. Nucleoside reverse transcriptase inhibitor (NRTI) (Correct Answer)
D. None of the options

Explanation: ***Nucleoside reverse transcriptase inhibitor (NRTI)*** - **Emtricitabine** is a synthetic nucleoside analog that inhibits the activity of HIV-1 **reverse transcriptase**, an enzyme essential for viral replication. - It works by being phosphorylated to its active triphosphate form, which then competes with natural deoxycytidine triphosphate for incorporation into the viral DNA, leading to **chain termination**. *Alkylating agent* - **Alkylating agents** are a class of antineoplastic drugs that work by adding an alkyl group to DNA, forming a covalent bond that interferes with DNA replication and transcription. - They are primarily used in **cancer chemotherapy**, not as antiviral agents for HIV. *Mitotic inhibitor* - **Mitotic inhibitors** are drugs that interfere with cell division (mitosis) by targeting microtubules, either inhibiting their polymerization or depolymerization. - These agents are also used in **cancer treatment** to prevent rapidly dividing cells from completing mitosis. *None of the options* - This option is incorrect because **emtricitabine** clearly belongs to the class of **nucleoside reverse transcriptase inhibitors**.

Question 1536: What is the recommended single dose treatment for gonorrhea?

A. Ceftriaxone (Correct Answer)
B. Erythromycin
C. Tetracycline
D. Azithromycin

Explanation: ***Ceftriaxone*** - **Ceftriaxone** is the **recommended first-line single dose treatment** for uncomplicated gonorrhea, given as a **500 mg intramuscular injection**. - As per current guidelines (CDC 2020+), **ceftriaxone monotherapy** is preferred due to its high efficacy and the discontinuation of routine dual therapy. - Ceftriaxone, a third-generation cephalosporin, maintains excellent activity against *Neisseria gonorrhoeae* with minimal resistance reported. *Azithromycin* - **Azithromycin alone** is **not recommended** as single-dose monotherapy for gonorrhea due to increasing macrolide resistance and treatment failures. - While previously used in dual therapy with ceftriaxone, routine dual therapy was discontinued in 2020 guidelines. - Azithromycin remains the first-line treatment for **chlamydia** (1 g single dose), which often co-occurs with gonorrhea and should be treated separately if detected. *Tetracycline* - **Tetracycline** is **not effective** against current strains of *Neisseria gonorrhoeae* due to widespread resistance. - Tetracyclines are primarily used for bacterial infections like **chlamydia** (doxycycline 100 mg twice daily for 7 days), **acne**, and **rickettsial infections**. *Erythromycin* - **Erythromycin** is **not a recommended treatment** for gonorrhea due to high rates of resistance and poor efficacy. - It is used for conditions like **streptococcal pharyngitis** in penicillin-allergic patients and some **atypical pneumonias**.

Question 1537: Which drug would be most appropriate for treating a patient with suspected chlamydia-gonorrhea coinfection?

A. Ciprofloxacin
B. Nalidixic acid
C. Doxycycline (Correct Answer)
D. Norfloxacin

Explanation: ***Doxycycline*** - **Doxycycline** is a highly effective treatment for **chlamydia**, and its broad-spectrum activity also covers potential **gonorrhea coinfection** when used as part of a dual therapy regimen. - It is often prescribed alongside a **single dose of ceftriaxone** for presumed gonorrhea coinfection, as ceftriaxone targets gonorrhea while doxycycline targets chlamydia. *Ciprofloxacin* - **Ciprofloxacin** is a **fluoroquinolone** antibiotic, which is generally not recommended as first-line treatment for uncomplicated **gonorrhea** or **chlamydia** due to increasing resistance. - It has activity against *Neisseria gonorrhoeae*, but its effectiveness against *Chlamydia trachomatis* is suboptimal compared to macrolides or tetracyclines. *Norfloxacin* - **Norfloxacin** is another **fluoroquinolone** with a narrower spectrum of activity than ciprofloxacin and is primarily used for **urinary tract infections**. - It has **poor efficacy against chlamydia** and is not a recommended treatment for either organism in this context. *Nalidixic acid* - **Nalidixic acid** is a first-generation **quinolone** with a very limited spectrum, used mainly for **gram-negative urinary tract infections**. - It has **no significant activity against chlamydia** or gonorrhea and is therefore inappropriate for treating this suspected coinfection.

Question 1538: What is the drug of choice for the treatment of kala-azar?

A. Amphotericin B
B. Quinine
C. Paromomycin
D. Liposomal Amphotericin B (Correct Answer)

Explanation: ***Liposomal Amphotericin B*** - It is currently considered the **drug of choice** for treating **visceral leishmaniasis (kala-azar)** due to its high efficacy and better tolerability profile compared to conventional amphotericin B. - The **liposomal formulation** allows for targeted delivery to macrophages, where *Leishmania* parasites reside, reducing systemic toxicity. *Amphotericin B* - While effective against *Leishmania*, conventional **Amphotericin B deoxycholate** is associated with significant **nephrotoxicity** and other severe side effects. - It is generally reserved for cases where liposomal amphotericin B is unavailable or as an alternative in specific clinical situations. *Quinine* - **Quinine** is an **antimalarial drug** primarily used for the treatment of *Plasmodium falciparum* malaria. - It has no significant efficacy against *Leishmania* species, which are the causative agents of kala-azar. *Paromomycin* - **Paromomycin** is an **aminoglycoside antibiotic** that can be used as an alternative treatment for visceral leishmaniasis, especially in combination therapies. - Although effective, it is generally not considered the first-line **drug of choice** globally, and its efficacy can vary by region.

Question 1539: XDR-TB is defined as resistance to which of the following drug combinations?

A. INH plus rifampicin
B. Fluoroquinolones plus INH plus amikacin
C. Fluoroquinolones plus rifampicin plus kanamycin
D. Fluoroquinolones plus INH plus rifampicin plus amikacin (Correct Answer)

Explanation: **Fluoroquinolones plus INH plus rifampicin plus amikacin** - **Extensively drug-resistant tuberculosis (XDR-TB)** is defined by resistance to the most effective anti-TB drugs: **isoniazid (INH)**, **rifampicin**, any **fluoroquinolone**, and at least one of the three injectable second-line drugs (**amikacin**, **kanamycin**, or **capreomycin**). - This combination signifies a substantial therapeutic challenge due to limited treatment options and a high risk of treatment failure. *INH plus rifampicin* - Resistance to **INH** and **rifampicin** defines **multidrug-resistant tuberculosis (MDR-TB)**, which is a precursor to XDR-TB but not XDR-TB itself. - While serious, MDR-TB is not as extensively resistant as XDR-TB, as it doesn't include resistance to fluoroquinolones and second-line injectables. *Fluoroquinolones plus INH plus amikacin* - This combination is incomplete for the definition of XDR-TB because it omits **rifampicin** from the core definition. - XDR-TB specifically requires resistance to both **INH** and **rifampicin** (defining MDR-TB), in addition to resistance to a fluoroquinolone and one of the injectable second-line drugs. *Fluoroquinolones plus rifampicin plus kanamycin* - This combination is also incomplete for the definition of XDR-TB as it omits **isoniazid (INH)**, which is one of the two most crucial first-line drugs that characterize MDR-TB. - XDR-TB builds upon MDR-TB's resistance to both INH and rifampicin.

Question 1540: What is the mechanism of action of aminoglycoside antibiotics?

A. Inhibition of protein synthesis (Correct Answer)
B. Inhibition of DNA replication
C. Disruption of the cell membrane
D. Inhibition of bacterial cell wall synthesis

Explanation: ***Inhibition of protein synthesis*** - Aminoglycosides **bind irreversibly to the 30S ribosomal subunit** of bacteria, interfering with the initiation complex formation and causing misreading of mRNA. - This leads to the production of **non-functional proteins** and ultimately bacterial cell death, making them bactericidal. *Disruption of the cell membrane* - This mechanism is characteristic of **polymyxins** (e.g., colistin), which interact with bacterial cell membranes, increasing permeability and causing leakage of intracellular contents. - Aminoglycosides do not primarily target the cell membrane for their bactericidal action. *Inhibition of DNA replication* - This mechanism is associated with **fluoroquinolones**, which inhibit bacterial topoisomerase II (DNA gyrase) and topoisomerase IV. - Aminoglycosides do not interfere with DNA synthesis or replication. *Inhibition of bacterial cell wall synthesis* - This is the mechanism of action for **beta-lactam antibiotics** (e.g., penicillins, cephalosporins) and **glycopeptides** (e.g., vancomycin), which target peptidoglycan synthesis. - Aminoglycosides do not affect the bacterial cell wall but rather their intracellular protein machinery.

Practice by Chapter

Beta-Lactam Antibiotics

Practice Questions

Aminoglycosides

Practice Questions

Macrolides and Ketolides

Practice Questions

Tetracyclines

Practice Questions

Quinolones

Practice Questions

Sulfonamides and Trimethoprim

Practice Questions

Antimycobacterial Drugs

Practice Questions

Antifungal Agents

Practice Questions

Antiviral Drugs

Practice Questions

Antiparasitic Agents

Practice Questions

Principles of Antimicrobial Selection

Practice Questions

Antimicrobial Resistance

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free